Adam Craig Purchases 86,206 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Chairman Adam Craig bought 86,206 shares of X4 Pharmaceuticals stock in a transaction on Thursday, October 23rd. The shares were purchased at an average cost of $2.90 per share, with a total value of $249,997.40. Following the completion of the purchase, the chairman directly owned 376,087 shares in the company, valued at $1,090,652.30. This trade represents a 29.74% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

X4 Pharmaceuticals Trading Up 1.9%

Shares of NASDAQ:XFOR opened at $3.81 on Wednesday. The company has a 50 day moving average of $3.40 and a 200-day moving average of $3.15. The firm has a market cap of $43.47 million, a P/E ratio of -0.26 and a beta of 0.54. X4 Pharmaceuticals, Inc. has a twelve month low of $1.35 and a twelve month high of $26.83. The company has a current ratio of 3.19, a quick ratio of 3.05 and a debt-to-equity ratio of 19.10.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Friday, August 8th. The company reported ($3.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.53) by $1.06. The company had revenue of $1.97 million during the quarter, compared to analyst estimates of $1.62 million. X4 Pharmaceuticals had a negative net margin of 311.15% and a negative return on equity of 375.31%. As a group, analysts anticipate that X4 Pharmaceuticals, Inc. will post -0.68 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. HC Wainwright set a $3.50 price target on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 13th. Zacks Research upgraded shares of X4 Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, October 21st. Stifel Nicolaus dropped their price objective on shares of X4 Pharmaceuticals from $30.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, August 29th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of X4 Pharmaceuticals in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, X4 Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $34.17.

Institutional Trading of X4 Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. Rhumbline Advisers lifted its holdings in shares of X4 Pharmaceuticals by 5.4% during the 1st quarter. Rhumbline Advisers now owns 188,415 shares of the company’s stock worth $44,000 after acquiring an additional 9,690 shares during the period. Bank of America Corp DE increased its position in shares of X4 Pharmaceuticals by 20.3% during the 4th quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after purchasing an additional 22,485 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in X4 Pharmaceuticals by 9.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company’s stock valued at $114,000 after acquiring an additional 43,320 shares in the last quarter. Jane Street Group LLC increased its position in X4 Pharmaceuticals by 112.5% in the 2nd quarter. Jane Street Group LLC now owns 97,344 shares of the company’s stock valued at $185,000 after acquiring an additional 51,544 shares in the last quarter. Finally, Pale Fire Capital SE increased its position in X4 Pharmaceuticals by 45.2% in the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company’s stock valued at $481,000 after acquiring an additional 633,398 shares in the last quarter. 72.03% of the stock is owned by institutional investors.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.